Krensavage Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Krensavage Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Buy	6,000 +2,000	+50%	+$1.36M	1.42%	14
2026 Q1	$3.09M	Hold	4,000	–	–	1.21%	16
2025 Q4	$3.09M	Hold	4,000	–	–	1.09%	15
2025 Q3	$2.25M	Hold	4,000	–	–	0.96%	15
2025 Q2	$2.1M	Buy	+4,000	New	+$2.23M	1.11%	15
2024 Q4	–	Sell	-353	Closed	-$371K	–	13
2024 Q3	$371K	Sell	353 -7,500	-96%	-$8.35M	0.21%	12
2024 Q2	$8.25M	Sell	7,853 -4,641	-37%	-$4.5M	3.79%	9
2024 Q1	$12M	Sell	12,494 -34,762	-74%	-$33.1M	5.33%	8
2023 Q4	$41.5M	Hold	47,256	–	–	14.73%	4
2023 Q3	$38.9M	Sell	47,256 -11,932	-20%	-$9.38M	14.32%	4
2023 Q2	$42.5M	Sell	59,188 -300	-0.5%	-$231K	13.47%	3
2023 Q1	$48.9M	Sell	59,488 -615	-1%	-$464K	14.84%	2
2022 Q4	$43.4M	Sell	60,103 -786	-1%	-$580K	13.4%	3
2022 Q3	$41.9M	Buy	60,889 +505	+0.8%	+$318K	13.36%	3
2022 Q2	$35.7M	Sell	60,384 -6,496	-10%	-$4.22M	11.8%	3
2022 Q1	$46.7M	Sell	66,880 -2,200	-3%	-$1.39M	16.1%	1
2021 Q4	$43.6M	Sell	69,080 -4,063	-6%	-$2.5M	15.13%	2
2021 Q3	$44.3M	Sell	73,143 -8,961	-11%	-$5.56M	13.89%	3
2021 Q2	$45.9M	Sell	82,104 -594	-0.7%	-$301K	15.57%	1
2021 Q1	$39.1M	Buy	82,698 +498	+0.6%	+$242K	13.54%	4
2020 Q4	$39.7M	Sell	82,200 -58	-0.1%	-$31.3K	11.6%	4
2020 Q3	$46M	Buy	82,258 +2,567	+3%	+$1.56M	14.66%	1
2020 Q2	$49.7M	Sell	79,691 -7,126	-8%	-$4.04M	13.52%	3
2020 Q1	$42.4M	Sell	86,817 -17,603	-17%	-$7.26M	13.64%	2
2019 Q4	$39.2M	Buy	+104,420	New	+$35.1M	13.38%	2

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Krensavage Asset Management's REGN Position: Q2 2026 in Review

Krensavage Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 50% in Q2 2026, buying an estimated $1.36M and bringing the position to 6,000 shares worth $3.74M. The position accounts for 1.42% of the portfolio, ranked #14.

Krensavage Asset Management first reported a position in REGN in Q4 2019 and has held it in 25 quarters since. The position peaked at $49.7M in Q2 2020. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Krensavage Asset Management held 6,000 shares of Regeneron Pharmaceuticals worth $3.74M as of Q2 2026.
Krensavage Asset Management bought 2,000 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36M.
Regeneron Pharmaceuticals made up 1.42% of Krensavage Asset Management's portfolio in Q2 2026, its #14 holding.
Krensavage Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
Krensavage Asset Management's Regeneron Pharmaceuticals position peaked at $49.7M in Q2 2020.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Krensavage Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.